A post market study for Boston Scientific's (Natick, Massachusetts) Taxus Liberté paclitaxel-eluting coronary stent system could not only further bolster the safety and efficacy of the FDA approved device, but in addition it could play a part in a much larger study of drug-eluting stents and dual antiplatelet therapies. The company reported yesterday, that nearly 1,500 of the 4,200 patients it is hoping to enroll for the post market study will participate in the DAPT intercompany study. (Medical Device Daily) Read More
